Perdue Pharma Will Profit From Medication-Assisted Treatment

Perdue Pharma makes Oxycontin, one of the most addictive prescription opioid drugs on the market. They’re a subject of many lawsuits and have been under Congressional investigation for their activities promoting opioid medications to doctors and other medical professionals. Many people say their company has made hundreds of millions of dollars fueling the addiction epidemic. However, the company has now started to dig into a new way to make money from the opioid epidemic. They’ve been quietly working to patent a new form of buprenorphine, a drug that is regularly used to help people get off of opioids. What is Perdue’s New Addiction Medication? In the recovery community, buprenorphine better known as a medication-assisted treatment when people take these drugs to stay clean. Perdue’s version is a “fast-acting” form of buprenorphine, which helps control drug cravings, according to CBS reported. While other versions of the drug are available in either tablet or dissolving strips, the Purdue version comes in a "wafer" that dissolves in only a few seconds.  …

Continue Reading

Lucemyra: FDA Approves New Medication-Assisted Treatment

Lucemyra has been on the market in the UK to assist with opioid withdrawal symptoms for about twenty years, but its use in the US has only just been approved. The FDA cleared the drug last Wednesday via fast-track to give American doctors another tool for fighting the opioid epidemic. Lucemyra alone is not to be considered treatment for opioid use disorder, the FDA says. However, clinical trials prove that it can reduce the severity of withdrawal symptoms that patients experience when they cease opioid use completely. This can give a person with an opioid use disorder a lifeline to help them get clean once and for all. Combined with therapy, 12-step programs and other tools, Lucemyra can help people find their way to recovery without the torment of many withdrawal symptoms. FDA Commissioner Dr. Scott Gottlieb says that this makes the drug an important tool that warranted quick approval. "The physical symptoms of opioid withdrawal can be one of the biggest barriers for patients seeking help and ultimately…

Continue Reading